Suppr超能文献

聚焦于现有 COVID-19 疫苗的技术、机制、安全性和有效性的综述。

A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines.

机构信息

Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; Department of Pharmaceutics, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

出版信息

Int Immunopharmacol. 2021 Nov;100:108162. doi: 10.1016/j.intimp.2021.108162. Epub 2021 Sep 17.

Abstract

20 months has been passed since the detection of the first cases of SARS-CoV-2 infection named COVID-19 from Wuhan city of China. This novel coronavirus spread rapidly around the world and became a pandemic. Although different therapeutic options have been considered and approved for the management of COVID-19 infection in different stages of the disease, challenges in pharmacotherapy especially in patients with moderate to severe COVID-19 and with underlying diseases have still remained. Prevention of infection through public vaccination would be the only efficient strategy to control the morbidity and mortality caused by COVID-19. To date, several COVID-19 vaccines using different platforms including nucleic acid-based vaccines, adenovirus-based vaccines, protein-based vaccines, and inactivated vaccines have been introduced among which many have received approval for prevention against COVID-19. In this comprehensive review, available COVID-19 vaccines have been discussed. The mechanisms, safety, efficacy, dosage, dosing intervals, possible adverse reactions, storage, and coverage of these four different vaccine platforms against SARS-CoV-2 variants have been discussed in detail and summarized in tabular format for ease of comparison and conclusion. Although each COVID-19 vaccine has various advantages and disadvantages over the others, accessibility and affordability of approved vaccines by the official health organizations, especially in developing countries, would be essential to terminate this pandemic. The main limitation of this study was the lack of access to the clinical data on available COVID-19 vaccines developed in Eastern countries since the data on their efficacy, safety, and adverse reactions were limited.

摘要

自 2020 年 1 月中国武汉首次发现新冠病毒(SARS-CoV-2)感染病例以来,已经过去了 20 个月。这种新型冠状病毒在全球迅速传播,成为一种大流行疾病。尽管已经考虑并批准了不同的治疗方案来治疗 COVID-19 感染的不同阶段,但在中度至重度 COVID-19 患者和患有基础疾病的患者中,药物治疗仍然存在挑战。通过公众接种疫苗来预防感染将是控制 COVID-19 发病率和死亡率的唯一有效策略。迄今为止,已经有几种使用不同平台的 COVID-19 疫苗问世,包括基于核酸的疫苗、腺病毒疫苗、基于蛋白质的疫苗和灭活疫苗,其中许多已获得预防 COVID-19 的批准。在本次全面综述中,讨论了现有的 COVID-19 疫苗。详细讨论了这四种不同疫苗平台针对 SARS-CoV-2 变体的机制、安全性、有效性、剂量、给药间隔、可能的不良反应、储存和覆盖范围,并以表格形式总结,以便于比较和得出结论。虽然每种 COVID-19 疫苗相对于其他疫苗都有各自的优缺点,但获得官方卫生组织批准的疫苗的可及性和可负担性对于终止这一大流行至关重要。本研究的主要局限性是无法获得来自东亚国家的已上市 COVID-19 疫苗的临床数据,因为关于它们的疗效、安全性和不良反应的数据有限。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1783/8445802/2c6f0135db69/ga1_lrg.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验